Transcripts of NK cell antigen receptors in nasal-type extranodal NK/T-cell lymphomas
Case no. . | Sex . | Age, y . | TCR . | CD3m . | CD56 . | 2dl4 . | 2d . | 3d . | CD94 . | 2A . | 2C . | 2D . | 2F . | LDH, IU/L . | WBC, 103/μL . | HB, g/dL . | PLT, 103/μL . | Stage . | Tx . | PF . | Course . | Sur . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD94+ | ||||||||||||||||||||||
| 1 | M | 38 | − | − | + | + | − | − | + | + | − | − | − | 378 | 5.9 | 14.1 | 170 | I | C | N | Progressive cranial nerve palsy, died of HPS | 7 |
| 2 | M | 69 | − | − | − | + | − | + | + | + | + | − | − | 360 | 3.6 | 14.3 | 112 | II | C | N | Progressive nasal and skin lesion, died | 9 |
| 3 | M | 42 | − | − | + | + | − | + | + | + | − | − | − | 715 | 2.4 | 7.6 | 167 | I | C + R | N | Progressive midfacial destruction, died | 24 |
| 4 | M | 55 | − | − | + | + | − | − | + | + | + | − | − | 304 | 5.2 | 13.2 | 192 | I | C | Y | CR for 5 y, recur and died of HPS | 60 |
| 5 | M | 65 | − | − | − | − | + | + | + | − | − | − | − | 406 | 5.9 | 11.7 | 317 | II | C | Y | CR for 5 y | 60+ |
| 6 | M | 59 | − | − | − | + | − | − | + | − | − | − | − | WNL | WNL | WNL | WNL | I | C + R | Y | CR for 4 y | 40+ |
| 7 | M | 24 | − | − | + | + | + | − | + | + | + | − | + | NA | NA | NA | NA | III | C + B | Y | CR for 7 y | 84+ |
| 8 | M | 28 | − | − | + | + | + | − | + | − | − | − | + | 489 | 3.5 | 14.1 | 218 | I | C | Y | Progression free | 18+ |
| 9 | F | 39 | − | − | − | + | − | − | + | + | − | − | − | 420 | 3.1 | 8.5 | 234 | I | C + B | Y | CR for 4 y | 48+ |
| 10 | F | 44 | − | − | − | − | − | + | + | − | − | − | − | 482 | 5.3 | 12.1 | 243 | I | C | Y | CR for 2 y | 24+ |
| CD94− | ||||||||||||||||||||||
| 1 | M | 60 | − | − | + | + | − | − | − | + | − | − | − | 932 | 6.9 | 12.1 | 227 | I | C + R | N | Progressive, died | 3 |
| 2 | M | 45 | − | − | + | + | − | + | − | − | − | − | − | WNL | WNL | WNL | WNL | I | C + R | N | Progressive LAP, died | 11 |
| 3 | M | 53 | − | − | − | − | + | − | − | − | − | − | − | 725 | 7.4 | 14.8 | 263 | I | C | N | Progressive lung meta, died | 11 |
| 4 | M | 66 | − | − | + | − | + | − | − | − | − | − | − | 309 | 10.9 | 10.3 | 174 | I | C | N | Progressive liver meta, died | 11 |
| 5 | M | 57 | − | − | + | − | + | − | − | − | − | − | − | 522 | 5.1 | 12 | 246 | I | C | N | multiple lung meta, died | 4 |
| 6 | M | 57 | − | − | − | − | + | − | − | − | − | − | − | 826 | 16.1 | 10.3 | 464 | II | C | N | Progressive bone marrow mėta, died | 4 |
| 7 | M | 61 | − | − | − | + | − | − | − | − | − | − | − | 527 | 7.2 | 13.1 | 283 | I | C | N | Progressive, died | 10 |
| 8 | M | 80 | − | − | + | − | − | + | − | − | − | − | − | NA | NA | NA | NA | I | C | Y | CR for 24 mo | 24+ |
| 9 | F | 55 | − | − | − | + | − | + | − | − | − | − | − | 595 | 6.7 | 13.1 | 268 | III | C | N | Progression, but still alive | 24+ |
| Mixed NK/T | ||||||||||||||||||||||
| 1 | M | 25 | + | − | + | + | − | + | − | + | − | − | − | 247 | 3.2 | 12 | 254 | I | C | N | Progressive LAP, died | 2 |
| 2 | M | 26 | + | − | + | + | − | − | − | − | − | − | − | 522 | 7.6 | 13.3 | 279 | I | C + B | N | Progressive, died | 11 |
| 3 | F | 20 | + | + | − | + | − | − | − | − | − | − | − | 400 | 4.7 | 12.5 | 157 | II | C + R | N | Progressive, died | 35 |
| 4 | F | 26 | + | + | − | − | + | − | − | − | − | − | − | NA | NA | NA | NA | I | C | Y | CR for 1 y | 12+ |
| 5 | F | 33 | + | − | − | + | − | + | − | − | − | − | − | 896 | 6.7 | 13.1 | 344 | I | C | Y | CR for 1 y | 12+ |
| 6 | F | 17 | + | + | − | + | − | − | − | − | − | − | − | WNL | WNL | WNL | WNL | I | C | Y | CR for 18 mo | 18+ |
Case no. . | Sex . | Age, y . | TCR . | CD3m . | CD56 . | 2dl4 . | 2d . | 3d . | CD94 . | 2A . | 2C . | 2D . | 2F . | LDH, IU/L . | WBC, 103/μL . | HB, g/dL . | PLT, 103/μL . | Stage . | Tx . | PF . | Course . | Sur . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD94+ | ||||||||||||||||||||||
| 1 | M | 38 | − | − | + | + | − | − | + | + | − | − | − | 378 | 5.9 | 14.1 | 170 | I | C | N | Progressive cranial nerve palsy, died of HPS | 7 |
| 2 | M | 69 | − | − | − | + | − | + | + | + | + | − | − | 360 | 3.6 | 14.3 | 112 | II | C | N | Progressive nasal and skin lesion, died | 9 |
| 3 | M | 42 | − | − | + | + | − | + | + | + | − | − | − | 715 | 2.4 | 7.6 | 167 | I | C + R | N | Progressive midfacial destruction, died | 24 |
| 4 | M | 55 | − | − | + | + | − | − | + | + | + | − | − | 304 | 5.2 | 13.2 | 192 | I | C | Y | CR for 5 y, recur and died of HPS | 60 |
| 5 | M | 65 | − | − | − | − | + | + | + | − | − | − | − | 406 | 5.9 | 11.7 | 317 | II | C | Y | CR for 5 y | 60+ |
| 6 | M | 59 | − | − | − | + | − | − | + | − | − | − | − | WNL | WNL | WNL | WNL | I | C + R | Y | CR for 4 y | 40+ |
| 7 | M | 24 | − | − | + | + | + | − | + | + | + | − | + | NA | NA | NA | NA | III | C + B | Y | CR for 7 y | 84+ |
| 8 | M | 28 | − | − | + | + | + | − | + | − | − | − | + | 489 | 3.5 | 14.1 | 218 | I | C | Y | Progression free | 18+ |
| 9 | F | 39 | − | − | − | + | − | − | + | + | − | − | − | 420 | 3.1 | 8.5 | 234 | I | C + B | Y | CR for 4 y | 48+ |
| 10 | F | 44 | − | − | − | − | − | + | + | − | − | − | − | 482 | 5.3 | 12.1 | 243 | I | C | Y | CR for 2 y | 24+ |
| CD94− | ||||||||||||||||||||||
| 1 | M | 60 | − | − | + | + | − | − | − | + | − | − | − | 932 | 6.9 | 12.1 | 227 | I | C + R | N | Progressive, died | 3 |
| 2 | M | 45 | − | − | + | + | − | + | − | − | − | − | − | WNL | WNL | WNL | WNL | I | C + R | N | Progressive LAP, died | 11 |
| 3 | M | 53 | − | − | − | − | + | − | − | − | − | − | − | 725 | 7.4 | 14.8 | 263 | I | C | N | Progressive lung meta, died | 11 |
| 4 | M | 66 | − | − | + | − | + | − | − | − | − | − | − | 309 | 10.9 | 10.3 | 174 | I | C | N | Progressive liver meta, died | 11 |
| 5 | M | 57 | − | − | + | − | + | − | − | − | − | − | − | 522 | 5.1 | 12 | 246 | I | C | N | multiple lung meta, died | 4 |
| 6 | M | 57 | − | − | − | − | + | − | − | − | − | − | − | 826 | 16.1 | 10.3 | 464 | II | C | N | Progressive bone marrow mėta, died | 4 |
| 7 | M | 61 | − | − | − | + | − | − | − | − | − | − | − | 527 | 7.2 | 13.1 | 283 | I | C | N | Progressive, died | 10 |
| 8 | M | 80 | − | − | + | − | − | + | − | − | − | − | − | NA | NA | NA | NA | I | C | Y | CR for 24 mo | 24+ |
| 9 | F | 55 | − | − | − | + | − | + | − | − | − | − | − | 595 | 6.7 | 13.1 | 268 | III | C | N | Progression, but still alive | 24+ |
| Mixed NK/T | ||||||||||||||||||||||
| 1 | M | 25 | + | − | + | + | − | + | − | + | − | − | − | 247 | 3.2 | 12 | 254 | I | C | N | Progressive LAP, died | 2 |
| 2 | M | 26 | + | − | + | + | − | − | − | − | − | − | − | 522 | 7.6 | 13.3 | 279 | I | C + B | N | Progressive, died | 11 |
| 3 | F | 20 | + | + | − | + | − | − | − | − | − | − | − | 400 | 4.7 | 12.5 | 157 | II | C + R | N | Progressive, died | 35 |
| 4 | F | 26 | + | + | − | − | + | − | − | − | − | − | − | NA | NA | NA | NA | I | C | Y | CR for 1 y | 12+ |
| 5 | F | 33 | + | − | − | + | − | + | − | − | − | − | − | 896 | 6.7 | 13.1 | 344 | I | C | Y | CR for 1 y | 12+ |
| 6 | F | 17 | + | + | − | + | − | − | − | − | − | − | − | WNL | WNL | WNL | WNL | I | C | Y | CR for 18 mo | 18+ |
TCR indicates T-cell receptor; CD3m, membrane CD3; 2d14, KIR2DL4; 2d, KIR2D; 3d, KIR3D; LDH, lactate dehydrogenase; WBC, white blood count; HB, hemoglobin; PLT, platelets; Tx, treatment; PF, progression free; Sur, survival in months; M, male; +, presence of transcript or surface marker; −, absence of transcript or surface marker; C, chemotherapy; N, no; HPS, hemophagocytic syndrome; R, radiotherapy; Y, yes; CR, complete remission; WNL, within normal limit; NA, not available; B, bone marrow transplantation; F, female; LAP, lymphadenopathy; meta, metastasis.
A + after the survival time indicates a censored case.